| Literature DB >> 24285955 |
Ana Raimunda Dâmaso1, Aline de Piano, Raquel Munhoz da Silveira Campos, Flávia Campos Corgosinho, Wolfgang Siegfried, Danielle Arisa Caranti, Deborah Cristina Landi Masquio, June Carnier, Priscila de Lima Sanches, Patrícia Leão da Silva, Cláudia Maria Oller Nascimento, Lila Missae Oyama, Alexandre Dâmaso Aguilera Dantas, Marco Túlio de Mello, Sergio Tufik, Lian Tock.
Abstract
The prevention of obesity and health concerns related to body fat is a major challenge worldwide. The aim of this study was to investigate the role of a medically supervised, multidisciplinary approach, on reduction in the prevalence of obesity related comorbidities, inflammatory profile, and neuroendocrine regulation of energy balance in a sample of obese adolescents. A total of 97 postpuberty obese adolescents were enrolled in this study. Body composition, neuropeptides, and adipokines were analysed. The metabolic syndrome was defined by the International Diabetes Federation (IDF). The abdominal ultrasonography was performed to measure visceral, subcutaneous fat and hepatic steatosis. All measures were performed at baseline and after one year of therapy. The multidisciplinary management promoted the control of obesity reducing body fat mass. The prevalence of metabolic syndrome, asthma, nonalcoholic fatty liver disease (NAFLD), binge eating, and hyperleptinemia was reduced. An improvement in the inflammatory profile was demonstrated by an increase in anti-inflammatory adiponectin and reduction in proinflammatory adipokines, plasminogen activator inhibitor-1, interleukin-6 concentrations, and in the Lep/Adipo ratio. Moreover, a reduction in the AgRP and an increase in the alfa-MSH were noted. The multidisciplinary approach not only reduced obesity but also is efficacious in cardiovascular risk factors, inflammatory profile, and neuroendocrine regulation of energy balance.Entities:
Year: 2013 PMID: 24285955 PMCID: PMC3826292 DOI: 10.1155/2013/541032
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Design conception of interdisciplinary therapy on obesity management in adolescents.
Figure 2Methodological description.
Prevalence of metabolic disorders associated with obesity.
| Variables | Baseline (%) | After therapy (%) |
| |
|---|---|---|---|---|
| Metabolic syndrome factors (IDF classification) | Glucose | 13 | 5 | <0.001 |
| Insulin | 23 | 4 | <0.001 | |
| Triglyceride | 17 | 7 | <0.001 | |
| HDL-cholesterol | 42 | 31 | 0.30 | |
| Systolic blood pressure | 26 | 5 | <0.001 | |
| Diastolic blood pressure | 14 | 2 | <0.001 | |
| Waist circumference | 62 | 14 | <0.001 | |
|
| ||||
| MS | Metabolic syndrome | 30 | 2 | <0.001 |
| Nonalcoholic fatty liver disease | 33 | 10 | <0.001 | |
|
| ||||
| Others complications | HOMA-IR | 83 | 40 | <0.001 |
| Hyperleptinemia | 75 | 55 | <0.001 | |
| Asthma | 16 | 0 | <0.001 | |
| Binge eating | 6 | 2 | <0.001 | |
Statistical significance P ≤ 0.05; HOMA-IR: homeostasis model assessment insulin-index resistance; HLD: high-density lipoprotein; IDF: International Diabetes Federation; MS: metabolic syndrome; NAFLD: nonalcoholic fatty liver disease.
Figure 3Prevalence of obesity complications: (a) metabolic syndrome factors; (b) comorbidities associated with obesity; *statistical significance, P < 0.05.
Effects of interdisciplinary therapy in body composition.
| Variables | Baseline | After therapy |
| Δ value |
|---|---|---|---|---|
| Body mass (kg) | 106.2 ± 16.2 | 94.4 ± 16.9 | <0.001 | −11.1 ± 7.7 |
| Height (m) | 1.68 ± 0.08 | 1.69 ± 0.08 | 0.07 | 0.009 ± 0.01 |
| BMI (kg/m²) | 37.0 ± 4.95 | 32.9 ± 5.32 | <0.001 | −4.27 ± 2.82 |
| Fat mass (kg) | 49.72 ± 11.66 | 36.5 ± 11.9 | <0.001 | −13.23 ± 7.02 |
| Fat mass (%) | 46.8 ± 5.70 | 38.0 ± 7.7 | <0.001 | −8.56 ± 4.58 |
| Free fat mass (kg) | 54.7 ± 10.4 | 57.0 ± 11.9 | <0.001 | 2.24 ± 4.29 |
| Free fat mass (%) | 53.1 ± 5.7 | 61.9 ± 7.7 | <0.001 | 8.74 ± 4.84 |
| Visceral fat (cm) | 4.5 ± 1.5 | 2.8 ± 1.3 | <0.001 | −1.60 ± 1.13 |
| Subcutaneous fat (cm) | 4.1 ± 0.8 | 3.2 ± 0.8 | <0.001 | −0.84 ± 0.80 |
| Waist circumference (cm) | 103.4 ± 10.7 | 94.9 ± 11.6 | <0.001 | −9.5 ± 18.32 |
| Systolic blood pressure (mmHg)* | 120 (100–190) | 110 (100–140) | <0.001 | −10.00 (−70–20) |
| Diastolic blood pressure (mmHg)* | 80 (70–110) | 70 (60–90) | <0.001 | 0.00 (−40–10) |
*Nonparametric data; BMI: body mass index; statistical significance P ≤ 0.05.
Effects of interdisciplinary therapy in metabolic profile (factors associated with metabolic syndrome definition by International Diabetes Federation (IDF)).
| Variables | Baseline | After therapy |
| Δ value |
|---|---|---|---|---|
| Waist circumference (cm) | 103.4 ± 10.7 | 94.4 ± 11.6 | <0.001 | −9.5 ± 18.32 |
| Glucose (mg/dL) | 90.5 ± 7.8 | 89.7 ± 7.7 | 0.43 | 0.77 ± 8.60 |
| Insulin ( | 17.1 ± 8.0 | 12.0 ± 9.6 | <0.001 | −4.94 ± 10.50 |
| HDL-cholesterol (mg/dL) | 43.7 ± 8.6 | 45.3 ± 9.2 | <0.001 | 1.80 ± 5.51 |
| LDL-cholesterol (mg/dL) | 102.4 ± 27.4 | 94.0 ± 24.0 | <0.001 | −9.98 ± 17.54 |
| VLDL-cholesterol (mg/dL) | 21.3 ± 9.4 | 17.8 ± 8.5 | <0.001 | −3.44 ± 8.06 |
| Triglyceride (mg/dL) | 111.2 ± 64.2 | 88.9 ± 42.6 | <0.001 | −21.27 ± 52.50 |
| HOMA-IR | 3.8 ± 2.0 | 2.7 ± 1.7 | <0.001 | −1.13 ± 3.00 |
HOMA-IR: homeostasis model assessment insulin-index resistance; HLD: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very-low-density lipoprotein. Reference values: glucose (60–110 mg/dL); insulin (<20 μU/mL); HOMA-IR (<2.0); total cholesterol (<170 mg/dL); Triglyceride (33–129 mg/dL); HDL cholesterol (>38 mg/dL); LDL cholesterol (<130 mg/dL); VLDL cholesterol (10–50 mg/dL) (2); statistical significance P ≤ 0.05.
Effects of interdisciplinary therapy in neuroendocrine regulation of energy balance and inflammatory profile.
| Variables | Baseline | After therapy |
| Δ value | |
|---|---|---|---|---|---|
| Neuroendocrine regulation of energy balance | AgRP (ng/mL) | 0.76 ± 1.45 | 0.55 ± 0.34 | <0.001 | 0.05 ± 0.14 |
| NPY (ng/mL) | 1.42 ± 1.75 | 1.55 ± 2.28 | 0.66 | 0.14 ± 2.82 | |
| NPY/AgRP ratio* | 0.41 (0.03–9.1) | 0.42 (0.01–5.33) | 0.07 | 0.02 (−2.47–2.86) | |
| MCH (ng/mL) | 4.14 ± 2.42 | 4.95 ± 2.50 | 0.80 | 0.45 ± 1.81 | |
|
| 0.99 ± 0.54 | 1.06 ± 0.75 | 0.03 | 0.10 ± 0.44 | |
| Ghrelin (ng/mL) | 1.10 ± 0.27 | 1.14 ± 0.24 | 0.40 | 0.02 ± 0.17 | |
| Leptin (ng/mL) | 42.59 ± 26.62 | 27.41 ± 20.48 | <0.001 | −19.77 ± 25.32 | |
|
| |||||
| Inflammatory profile | Adiponectin ( | 6.61 ± 3.61 | 7.42 ± 4.61 | <0.001 | 1.63 ± 2.69 |
| Lep/Adipo ratio* | 5.7 (0.15–44.3) | 3.7 (0.16–30.9) | <0.001 | −10.48 (5.64–36.41) | |
| TNF- | 44.31 ± 78.9 | 29.25 ± 41.45 | 0.23 | −15.05 ± 52.03 | |
| CRP (ng/mL) | 6.38 ± 11.34 | 8.75 ± 14.87 | 0.48 | 1.82 ± 17.36 | |
| Resistin (ng/mL) | 12.45 ± 10.5 | 13.10 ± 10.3 | 0.71 | 0.22 ± 4.88 | |
| PAI-1 (ng/mL) | 13.4 ± 8.1 | 9.6 ± 8.3 | <0.001 | −3.94 ± 6.00 | |
| interleukin-6 (IL-6) | 58.3 ± 46.9 | 32.4 ± 21.7 | 0.05 | −25.88 ± 49.85 | |
*Nonparametric data; statistical significance P ≤ 0.05; AgRP: Agouti-related peptide; NPY: neuropeptide Y; MCH: melanin-concentrating hormones; α-MSH: α-melanocyte-stimulating hormone; Lep/Adipo ratio: leptin/adiponectin ratio; TNF-α: tumor necrosis factor-alpha; CRP: C-reactive protein; PAI-1: plasminogen activator inhibitor-1. Reference values: Leptin values between 1 and 20 ng/ml for males and between 4.9 and 24 ng/ml for females.
Correlations analysis.
| Variables (Δ values) |
|
| |
|---|---|---|---|
| Fat mass (kg) | Free fat mass (%) | −0.75 | 0.001 |
| Adiponectin ( | −0.72 | 0.001 | |
| Lep/Adipo ratio | 0.67 | 0.003 | |
| Visceral fat (cm) | −0.57 | 0.871 | |
|
| |||
| Subcutaneous fat (cm) | Fat mass (%) | 0.71 | 0.002 |
| Free fat mass (%) | −0.71 | 0.002 | |
|
| |||
| Adiponectin ( | Body mass (kg) | −0.65 | 0.003 |
| Visceral fat (cm) | −0.20 | 0.571 | |
| HOMA-IR | −0.20 | 0.873 | |
|
| |||
| PAI-1 (ng/mL) | Ghrelin (ng/mL) | 0.68 | 0.002 |
|
| |||
| Visceral fat (cm) | HOMA-IR | 0.67 | 0.572 |
| Fat mass (%) | −0.28 | 0.421 | |
Lep/Adipo ratio: leptin/adiponectin ratio; PAI-1: plasminogen activator inhibitor-1; HOMA-IR: homeostasis model assessment insulin index-resistance; statistical significance P ≤ 0.05.